BACKGROUND AND OBJECTIVES: Among B-cell malignancies, follicular lymphomas (FL) more frequently show acquired, potential N-glycosylation sites (AGS) within tumor-specific immunoglobulin. The aim of this study was to extend this observation and to evaluate the pattern of presentation of AGS within five different forms of B-cell lymphoma. DESIGN AND METHODS: We sequenced the tumor-specific immunoglobulin heavy chain variable region fragment, including complementarity-determining regions 2 and 3, of forty-seven consecutive patients with a B-cell malignancy enrolled in idiotype vaccine clinical trials. This sequencing approach is known to allow the identification of most AGS. We then statistically analyzed differences in presentation pattern, in terms of tumor histology, immunoglobulin isotype, AGS location and amino acid composition. RESULTS: All twenty-four FL cases presented with at least one AGS, whereas the vast majority of four B-cell lymphoma types other than FL did not. The non- FL group of tumors included four cases of Burkitt's lymphoma, six of diffuse large cell lymphoma, seven mantle cell lymphomas and six small lymphocytic lymphomas. Most IgM-bearing follicular lymphoma cases featured their AGS within complementarity-determining region 2, as opposed to those bearing an IgG, which mostly displayed the AGS within complementarity-determining region 3. The vast majority of AGS located within either complementarity-determining region ended with a serine residue, whereas those located within framework regions mostly featured threonine as the last amino acid residue. INTERPRETATION AND CONCLUSIONS: In our series, all cases of FL had AGS within their tumor-specific immunoglobulin heavy chain variable regions. In contrast, most B-cell malignancies other than FL did not. Further studies are warranted in order to establish the possible meaning of these findings in terms of disease pathogenesis, their diagnostic value in doubtful cases and their potential implications for immunotherapy.
BACKGROUND AND OBJECTIVES: Among B-cell malignancies, follicular lymphomas (FL) more frequently show acquired, potential N-glycosylation sites (AGS) within tumor-specific immunoglobulin. The aim of this study was to extend this observation and to evaluate the pattern of presentation of AGS within five different forms of B-cell lymphoma. DESIGN AND METHODS: We sequenced the tumor-specific immunoglobulin heavy chain variable region fragment, including complementarity-determining regions 2 and 3, of forty-seven consecutive patients with a B-cell malignancy enrolled in idiotype vaccine clinical trials. This sequencing approach is known to allow the identification of most AGS. We then statistically analyzed differences in presentation pattern, in terms of tumor histology, immunoglobulin isotype, AGS location and amino acid composition. RESULTS: All twenty-four FL cases presented with at least one AGS, whereas the vast majority of four B-cell lymphoma types other than FL did not. The non- FL group of tumors included four cases of Burkitt's lymphoma, six of diffuse large cell lymphoma, seven mantle cell lymphomas and six small lymphocytic lymphomas. Most IgM-bearing follicular lymphoma cases featured their AGS within complementarity-determining region 2, as opposed to those bearing an IgG, which mostly displayed the AGS within complementarity-determining region 3. The vast majority of AGS located within either complementarity-determining region ended with a serine residue, whereas those located within framework regions mostly featured threonine as the last amino acid residue. INTERPRETATION AND CONCLUSIONS: In our series, all cases of FL had AGS within their tumor-specific immunoglobulin heavy chain variable regions. In contrast, most B-cell malignancies other than FL did not. Further studies are warranted in order to establish the possible meaning of these findings in terms of disease pathogenesis, their diagnostic value in doubtful cases and their potential implications for immunotherapy.
Authors: Susana Inoges; Ascension Lopez-Diaz de Cerio; Helena Villanueva; Fernando Pastor; Elena Soria; Maurizio Bendandi Journal: World J Clin Oncol Date: 2011-06-10
Authors: A Zamò; J Pischimarov; M Schlesner; P Rosenstiel; R Bomben; H Horn; T Grieb; T Nedeva; C López; A Haake; J Richter; L Trümper; C Lawerenz; W Klapper; P Möller; M Hummel; D Lenze; M Szczepanowski; L Flossbach; M Schreder; V Gattei; G Ott; R Siebert; A Rosenwald; E Leich Journal: Leukemia Date: 2017-08-21 Impact factor: 11.528
Authors: Vania Coelho; Sergey Krysov; Amir M Ghaemmaghami; Mohamed Emara; Kathleen N Potter; Peter Johnson; Graham Packham; Luisa Martinez-Pomares; Freda K Stevenson Journal: Proc Natl Acad Sci U S A Date: 2010-10-11 Impact factor: 11.205
Authors: Caleigh Mandel-Brehm; Miriam L Fichtner; Ruoyi Jiang; Valerie J Winton; Sara E Vazquez; Minh C Pham; Kenneth B Hoehn; Neil L Kelleher; Richard J Nowak; Steven H Kleinstein; Michael R Wilson; Joseph L DeRisi; Kevin C O'Connor Journal: J Immunol Date: 2021-09-20 Impact factor: 5.426
Authors: Dunja Schneider; Marcus Dühren-von Minden; Alabbas Alkhatib; Corinna Setz; Cornelis A M van Bergen; Marco Benkißer-Petersen; Isabel Wilhelm; Sarah Villringer; Sergey Krysov; Graham Packham; Katja Zirlik; Winfried Römer; Christian Buske; Freda K Stevenson; Hendrik Veelken; Hassan Jumaa Journal: Blood Date: 2015-03-17 Impact factor: 22.113